Your trusted destination for CME, CPD & Medical Education across the Middle East.
Marmara University School of Medicine (Istanbul, Türkiye) & Chief Medical Officer at Genalyse
Prof. Dr. Safa Baris is an internationally distinguished physician-scientist, professor of pediatric allergy and immunology, and global leader in the diagnosis and management of primary immunodeficiencies (PIDs) and primary immune regulatory disorders (PIRDs). He earned his Doctor of Medicine (MD) degree and completed specialized residency training in pediatrics before undertaking advanced subspeciality fellowship training in pediatric allergy and immunology.Over two decades of academic and clinical practice, Dr. Baris has dedicated his career to unraveling the genetic, molecular, and immunologic underpinnings of rare inherited immune disorders.
Currently serving as Full Professor in the Division of Pediatric Allergy and Immunology at Marmara University in Istanbul, Türkiye, Dr. Baris leads a nationally accredited referral center and research laboratory for severe inborn errors of immunity. His clinical practice focuses on diagnosing and treating complex monogenic autoimmune and autoinflammatory conditions, severe combined immunodeficiencies (SCID), hyper-IgE syndromes (HIES), activated PI3K delta syndrome (APDS), and IPEX/IPEX-like lymphoproliferative syndromes. In addition to his academic post, he serves as Chief Medical Officer at Genalyse, guiding precision genomic diagnostics and translational biotechnology.
As an active researcher, Dr. Baris has authored over 200 high-impact scientific publications in top-tier medical journals, including Nature Immunology, Science Immunology, The Journal of Allergy and Clinical Immunology (JACI), and Frontiers in Immunology. His scientific breakthroughs include identifying novel gene defects—such as loss-of-function ZNF341 mutations regulating JAK-STAT signaling—and defining key clinical characteristics within global registries like the European Society for Immunodeficiencies (ESID). His lab routinely integrates whole-exome sequencing (WES), whole-genome sequencing (WGS), transcriptomics, and high-dimensional functional assays to bridge the diagnostic gap for undiagnosed pediatric patients across the Middle East and Southern Europe.
Beyond his primary research laboratory, Dr. Baris is a prominent voice in international immunology networks, collaborating regularly with global consortia, including the International Union of Immunological Societies (IUIS) and the Middle East and North Africa Diagnosis and Management Networks. He acts as a mentor for international clinical fellows and frequently serves on scientific steering committees to standardize clinical care guidelines, biological treatment strategies, and bone marrow transplantation protocols for children with life-threatening immunodysregulation.
At RAPID 2026: Recent Advances in Primary Immunodysregulation Disorders, hosted by Sidra Medicine, Dr. Baris brings his extensive translational immunology background to the international scientific platform. In his keynote address, "Leveraging Omics Technologies in PIRD Diagnosis and Care", he presents cutting-edge workflows for integrating multi-omics data into routine clinical practice, evaluating targeted small-molecule inhibitors and biologics (such as JAK inhibitors and CTLA-4 Ig fusion proteins), and establishing precision medicine frameworks to improve survival and quality of life for children affected by PIRDs globally.

Sidra Medicine
Sidra Medicine